drugset / Trial / NCT01949935

Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

NCT01949935

Phase 3 Completed 974 enrolled Horizon Health Network
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The hypothesis is that application of Mupirocin to the nose before and after coronary artery bypass grafting surgery will reduce the incidence of surgical site infections.

Timeline

Start
2009-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mupirocin Small molecule Intranasal

Indications

No indication recorded.